Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Inflation Reduction Act: Reforms to patient cost-sharing
The Inflation Reduction Act (IRA) of 2022 contains some of the most significant changes in healthcare regulation since the introduction of the Medicare...